Stanoprime Instructions for Use, Analogues, Composition, Indications

Treatment with Stanoprime should be carried out under the constant supervision of a physician experienced in the diagnosis and treatment of patients with Stanoprime deficiency. Patients with intra- and extracranial neoplasms during remission who receive growth hormone therapy should be monitored by a doctor at regular intervals.

Patients with Stanoprime deficiency as a result of intracranial neoplasms receiving therapy with Stanoprime should be regularly examined for progression or recurrence of the underlying disease.

Prader-Willi Syndrome

Stanoprime is not intended for the long-term treatment of pediatric patients with growth retardation as a result of confirmed Prader-Willi syndrome, even if there is a confirmed deficit of Stanoprime. Cases of respiratory failure during sleep with deaths after the start of growth hormone therapy have been reported in pediatric patients with Prader-Willi syndrome and the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, unidentified respiratory infections Leukemia

Cases of leukemia have been reported in some patients with Stanoprime deficiency, some of whom received Testobolin therapy. However, at the moment there is no evidence that the risk of leukemia depends on the use of Stanoprime.

Stanoprime Insulin Sensitivity

Since Stanozolol decreases receptor sensitivity to insulin, patients should be regularly examined for impaired glucose tolerance. In persons with diabetes mellitus or a family history of diabetes mellitus, the drug should be administered with caution. Patients with diabetes mellitus may need to adjust the dose of insulin after the start of therapy with homo growth.

Stable retinopathy should not be a reason to discontinue Stanozolol therapy. In the event of preproliferative changes or the presence of proliferative retinopathy, growth hormone therapy should be discontinued.

Thyroid Function of Stanoprime

The use of Stanoprime enhances the extra-thyroid conversion of T4 to T3. And may, in particular, unmask hypothyroidism. Thyroid gland function monitoring should be performed in all patients. Thyroid function should be assessed before starting therapy and regularly checked during treatment. In patients with impaired pituitary function, standard replacement therapy should be tightly controlled against the background of therapy with growth hormone.

Benign Intracranial Hypertension

If severe or persistent headaches, visual impairment, nausea, and / or vomiting occur, fundoscopy should be performed to detect edema of the optic nerve. A study of the fundus of the eye must be carried out before starting Stanoprime therapy (to exclude the existing optic nipple edema) and be repeated later if the pathology is suspected. If optic nerve papilla is detected, treatment with Stanozolol should be discontinued. Treatment can be resumed at lower doses after the elimination of benign intracranial hypertension (which usually passes quickly after discontinuation of the drug). In this case, the patient should be monitored for the occurrence of symptoms of benign intracranial hypertension, and if this complication recurs, treatment should be discontinued.

Stanoprime Antibodies

A small percentage of patients receiving Stanozolol-containing products showed the appearance of antibodies to Stanozolol. The binding capacity of this type of antibody was low and did not affect the growth rate. Despite this, all patients with no effect on the use of Stanoprime should be examined for antibodies.

Epiphysiolysis of the femoral head is often associated with endocrine disorders such as Stanoprime deficiency, and psothyroidism. In children treated with growth hormone, epiphysiolysis of the femoral head can be the result of both endocrine disruption and an increase in skeletal growth rate. A sharp increase in growth rates can be the cause of joint problems. The attending physician and parents should keep this fact out of attention and be wary of child complaints about pains in the hip and / or knee joints during treatment with Stanoprime.

Patients with growth retardation on the background of chronic renal failure should be regularly examined for progression of renal osteodystrophy. Epiphysiolysis of the femoral head or aseptic necrosis of the femoral head can be observed in children with severe renal osteodystrophy. At present, the relationship of the occurrence of these complications with growth hormone therapy has not been fully established. X-ray examination of the hip joints should be carried out in such patients before the start of therapy.

In children with chronic renal failure, renal function should be reduced by 50% or more before starting therapy. To verify growth impairment, the growth rate should be monitored for 1 year prior to treatment. Conservative treatment of renal failure should be carried out within 1 year prior to the start of therapy and maintained throughout the entire period of treatment. Therapy should be suspended at the time of the kidney transplant.

In children diagnosed with growth retardation as a result of intrauterine growth retardation before starting treatment, other causes of stunting should be excluded.

In children diagnosed with growth retardation as a result of intrauterine growth retardation, the level of serum insulin and glucose should be determined on an empty stomach before the start of Trenbolin treatment and should be performed annually. In the presence of diabetes, Stanoprime treatment is not recommended.

In children diagnosed with growth retardation as a result of intrauterine growth retardation before starting treatment and then twice a year, it is recommended to determine the level of insulin-like growth factor. In case if the level of insulin-like factor of the robot reaches +2 standard deviations in comparison!

indicators and adolescent status, the results of this study should be taken into account when adjusting the dose.

The experience of treating patients with intrauterine growth retardation in history, subject to the start of treatment in adolescence, is limited. Experience in the treatment of patients with intrauterine growth retardation in history in combination with Silver-Roussel syndrome is limited.

In adults, growth hormone therapy may experience fluid retention in the body.

In case of persistent edema and severe paresthesia, the dose should be reduced in order to avoid carpal tunnel syndrome.

Injection sites should be changed to avoid lipoatrophy.

The final growth of children diagnosed with growth retardation as a result of intrauterine growth retardation will not be achieved if Stanoprime treatment is discontinued before reaching the final growth.

The introduction of the drug in the same place over a long period of damage to this area of the skin. It is important to constantly change the place of injection.

Stanoprime should not be used in case of urgent conditions.

Patients older than 60 years old who are receiving Stanoprime therapy for a long period should be under close supervision, since experience with Stanoprime in elderly patients is insufficient.

Impact on the ability to drive vehicles and work with mechanisms

Stanoprime does not affect the ability to drive and work with mechanisms.

Recommended Winstrol Depot Products